Quest Diagnostics Declares Dividend While Advancing Public Health Initiatives and Innovations

Quest Diagnostics Reinforces Commitment to Public Health with Quarterly Dividend and Innovative Initiatives

On November 11, 2025, Quest Diagnostics, a leader in diagnostic information services, announces a quarterly cash dividend of $0.80 per share, scheduled for payment on January 28, 2026. This dividend reflects the company's ongoing dedication to shareholder value while underscoring its commitment to enhancing health outcomes through advanced diagnostic insights. As a company that serves one in three adult Americans and collaborates with a vast network of healthcare providers, Quest Diagnostics continues to focus on utilizing its extensive database of de-identified clinical lab results to influence public health positively.

With a workforce exceeding 55,000 employees, Quest Diagnostics is at the forefront of transforming healthcare through innovative diagnostic solutions. The company emphasizes that its services empower individuals and organizations to identify and treat diseases more effectively, promoting healthier behaviors and improving overall healthcare management. The insights drawn from its extensive database not only facilitate better clinical decisions but also inspire actions that contribute to healthier lives. This commitment to leveraging diagnostic information aligns seamlessly with Quest Diagnostics' mission to create a healthier world, one life at a time.

In addition to the dividend announcement, Quest Diagnostics is actively engaged in various initiatives aimed at advancing public health. The company is set to participate in Citi's 2025 Global Healthcare Conference, showcasing its commitment to collaboration within the healthcare sector. Furthermore, Quest is developing advanced diagnostic tests, such as the AD-Detect® test for Alzheimer's disease, which highlights its focus on addressing critical health challenges. These initiatives underline the company’s strategic direction towards innovation in diagnostics, ensuring that it remains a pivotal player in the healthcare landscape.

In summary, Quest Diagnostics not only affirms its financial health through a consistent dividend but also demonstrates its unwavering dedication to public health improvement. By investing in advanced diagnostic technologies and participating in key healthcare conferences, the company continues to position itself as a leader in the diagnostic industry. Interested parties can learn more about Quest Diagnostics and its initiatives by visiting their website at www.QuestDiagnostics.com.